Dolores Schendel – VJRegenMed

Selecting TCRs: understanding peptide-HLA-TCR interactions

admin_vjr_user — Mon, 17 May 2021 11:34:07 +0000

Dolores J. Schendel, PhD, Medigene, Planegg, Germany, provides an overview of her presentation at the CAR-TCR Summit Europe 2021 and describes the tripartide interactions that take place between the peptide, human leukocyte antigen (HLA) molecule and the T-cell receptor (TCR), which largely govern the activity of TCR-engineered T (TCR-T) cell therapies. She also explains the importance of the cross-presentation process and discusses some of the key factors that must be considered when selecting TCRs for use in TCR-T cell therapies for solid tumors. This interview took place during the CAR-TCR Summit Europe 2021.

How the TCR field can learn from CARs

admin_vjr_user — Wed, 24 Mar 2021 19:15:31 +0000

Dolores J. Schendel, PhD, Medigene, Planegg, Germany, provides an overview of how the field of T-cell receptor (TCR) therapy research has evolved in recent years and continues to benefit and learn from challenges already faced in the chimeric antigen receptor (CAR) field in terms of logistics, infrastructure and regulation. She also discusses the potential TCR therapies have in targeting solid tumors and how TCR engineering and their use in combination therapies could lead to significant advances in the future. This interview took place during the CAR-TCR Summit Europe 2021.

PD1-41BB switch receptor expression in the treatment of PD-L1-positve solid tumors

admin_vjr_user — Wed, 24 Mar 2021 19:15:30 +0000

Dolores J. Schendel, PhD, Medigene, Planegg, Germany, describes research into the expression of a chimeric PD1-41BB switch receptor, which combines the co-stimulatory domain of 4-1BB with the extracellular domain of PD-1, on therapeutic T-cell receptor (TCR)-engineered T cells (TCR-Ts) with the aim of enhancing their clinical efficacy in the treatment of PD-L1-positive solid tumors. Preclinical research indicates that the expression of this chimeric switch receptor combats the inhibitory signal induced by the PD-1/PD-L1 interaction on the tumor cell and enhances TCR-T functionality in the tumor microenvironment by reducing T cell exhaustion and improving the metabolic fitness of T cells. This interview took place during the CAR-TCR Summit Europe 2021.